Patient Benefit

Patient Benefit

Modra aims to maintain the effectiveness of taxane therapy while reducing the significant burdens that patients experience

Modra Pharmaceuticals

Patient Benefit

Taxane therapy is an effective mainstay of anti-cancer treatment for many cancer patients but is accompanied by significant drawbacks which negatively affect patients’ lives during times that are already very challenging due to the nature of their disease.

Modra aims to maintain the effectiveness of taxane therapy while reducing the significant burdens that patients experience in terms of lifestyle and side-effects, with the goal of not only successfully treating their disease but also helping them to push their therapy into the background of, rather than having it dominate, their lives.

Achieving patient benefit
in several ways

Reduction of serious toxicities

Modra seeks to reduce and in some cases eliminate serious toxicities which are often associated with taxane therapy, including severe neutropenia and neuropathy (which can be “dose-limiting”, prematurely ending or reducing a patient’s therapy even if it is working against the tumor), hair loss, hypersensitivity and infusion-related reactions. This it achieves by two methods (i) eliminating common toxic excipients used in IV formulations, from the formulation of its oral taxanes; (ii) changing the pharmacokinetics of the drug to reduce certain toxicities mentioned above. Modra can achieve the same level of systemic exposure to the anti-cancer therapy at a peak concentration of the drug which is less than 5% of the IV formulation.

Boosted taxanes as tablets

Modra’s boosted taxanes are orally administered as tablets. This, of course – in combination with lower toxicities – should enable patients to take their treatment from the comfort of their homes. The avoidance of daycare hospitalization for IV-administration can not only positively impact patient quality of life, but also reduce time away from work, decrease healthcare costs and also free up the accessibility to critical care facilities for other patients. This benefit has been further highlighted during the COVID-19 pandemic where vulnerable populations would now be able to avoid further risk to their wellbeing by not having to visit a clinic or health center to receive IV chemotherapy.

Safer, patient-friendly, and

Transitioning from IV to boosted oral taxane therapy has the opportunity to transform standard of care for the better. Modra’s oral formulation has the potential to be the safer, patient-friendly, and cost-efficient alternative to IV-administered anti-cancer drugs.

Further, as cancer regimens increasingly include a number of drugs used in combinations, providing a reliable oral formulation of taxane therapies can also provide important dosing flexibility for clinicians, either in sequence with other therapies or in potential new all-oral combinations.